AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 156 min read$CGCNeutralMed

Canopy Growth Corp (CGC): Results of Operations and Financial Condition

Canopy Growth Corp (CGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cgc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis Full-year 2026 growth driven by net revenue

AI DeskJune 15, 2026
AI analysis
Relevance
7/10
Novelty
8/10
Actionability
Med
Sentiment · $CGC
Neutral
Timing
Filed June 15, 2026 (8-K) with Q4 FY2026 and FY2026 financial results
Market alignment
Improves balance-sheet risk profile (net cash) but highlights margin compression and impairment/restructuring costs
Why this matters for $CGC

Earnings-style update with balance-sheet improvement and margin pressure; acquisition of MTL Cannabis and cost actions are central to the narrative.

Relevance context

Canopy Growth reports Q4 FY2026 and FY2026 results, including net revenue growth, gross margin decline, and a $131.3M net cash position after recapitalization.

Price-impact prediction

Near-term trading likely hinges on whether investors focus more on revenue growth/net cash versus the sharp gross margin and inventory charge deterioration.

Background

This is an SEC Form 8-K (Item 2.02) with Canopy Growth’s Q4 FY2026 and FY2026 financial results and related operational highlights, including the MTL Cannabis acquisition and balance-sheet recapitalization.

Why it matters

The most tradable elements are the quantified revenue growth, margin deterioration (including inventory charges), large impairment/restructuring costs, and the shift to a net cash position, alongside the stated goal of positive Adjusted EBITDA during fiscal 2027.

Market relevance

Traders will likely reprice CGC around the tension between improved net cash and revenue growth versus weaker gross margins and integration-related charges, with FY2027 profitability as the forward anchor.

Market effects

Sector

Cannabis operators may see read-across on how acquisitions and inventory write-offs affect reported margins and adjusted EBITDA trajectories.

Regional

Canada medical growth and international supply-chain execution are emphasized, potentially influencing investor focus on cross-border cannabis execution risk.

Global

International market performance is mixed (international revenue down FY despite Q4 growth), relevant for global cannabis platform investors.

Alternative perspectives

Contrarian view

Revenue growth may be less durable given gross margin compression, inventory charges, and impairment/restructuring costs tied to integration and product/mix shifts.

Overlooked factors

Storz & Bickel segment weakness (tariffs, geographic mix) and the impact of reduced Veterans Affairs Canada reimbursement could be the key swing factors for forward earnings quality.

Key entities

  • issuer
    Canopy Growth Corporation

    Reports Q4 FY2026 and FY2026 financial results, acquisition of MTL Cannabis, and balance-sheet strengthening to net cash.

  • acquired_company
    MTL Cannabis

    Acquisition referenced as driving inventory step-up and positioning Canopy as a leading Canadian medical cannabis provider by revenue.

  • brand_segment
    Storz & Bickel

    Vape/related segment with declining net revenue and gross margin, attributed to lapping prior-year sales and tariffs/geographic mix.

Read at source← All news

Related articles

JUN 15
$CGCMed

Cannabis Catalysts: Canopy Growth's FY2026 Revenue Climbs as High Tide Adds Four Ontario Stores

Canopy Growth reported Q4 FY2026 net revenue of C$71.2 million (+10% YoY) and full-year revenue of C$284.6 million (+6%). Canada medical revenue rose 27% to C$25.3 million and international revenue rose 68% to C$8.6 million. Canopy ended FY2026 with C$131.3 million net cash and expects positive Adjusted EBITDA in FY2027. High Tide agreed to buy four Ontario stores for C$7.74 million, adding to 228 Canna Cabana locations in Canada and 103 in Ontario, pending TSXV and AGCO approvals.

investorideas.com6 min
JUN 2
$CGCMedAI 8/10

Canopy Growth Still Looks Broken -- But These 3 Numbers Suggest a Turnaround May Be Starting

Canopy Growth (CGC) remains down over 95% from its all-time highs and still reports net losses, amid Canada’s oversupplied, discounting-heavy cannabis market, according to the article. It cites an adjusted EBITDA loss of about $2.17 million in the latest quarter (improved vs. prior years), 15% year-over-year growth in Canadian medical cannabis revenue, and about $230 million cash plus a ~$50 million debt prepayment.

finance.yahoo.com7 min
JUN 2
$CGCLow

The Market Overreacted to the DEA's Marijuana Rescheduling -- Here's What It Means for Canopy Growth Stock Now

The DEA rescheduled U.S. medical marijuana from Schedule I to Schedule III in late April, a change that the article says has had limited market impact so far. The shift removes IRS Section 280E limits on medical cannabis deductions, but exports remain tightly restricted by Health Canada. For Canopy Growth, U.S. medical sales sit in Canopy USA, where it holds a non-controlling stake, so results aren’t consolidated.

fool.com6 min
JUN 2
$CGCLow

Canopy Growth Corp (CGC) Expands Its Medical Products Lineup

Canopy Growth (NASDAQ:CGC) said May 7 it expanded its medical cannabinoid softgel lineup, adding new 30-pack and 90-pack formats and introducing additional dosing options, according to the company. Canopy cited strong performance of its existing 30-pack and said the changes aim to improve patient access and affordability. Products are distributed via Spectrum Therapeutics.

finance.yahoo.com4 min
JUL 17
$BIDUMed

Baidu advances Hong Kong dual primary listing plans, shares climb (BIDU)

Baidu said its board approved a plan to convert its Hong Kong listing to a dual primary listing with Nasdaq. The company expects completion in 2026, subject to regulatory and exchange requirements. Baidu’s Class A shares and ADSs would continue trading on their respective exchanges and remain fungible. Shares rose about 4% in premarket.

yahoo.com2 min
JUL 17
$FFINMed

FIRST FINANCIAL BANKSHARES INC (FFIN): Results of Operations and Financial Condition

FIRST FINANCIAL BANKSHARES INC (FFIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ffin-ex99_1.htm EX-99.1 EX-99.1 For immediate release For More Information: Michelle S. Hickox, EVP & Chief Financial Officer 325.627.7155 FIRST FINANCIAL BANKSHARES ANNOUNCES SECOND QUARTER 2026 EARNINGS ABILENE, Texas, July 16, 2026 - First Financial Bankshares, Inc.

SEC EDGAR 8-K4 min